Eternal and Zomato founder Deepinder Goyal's wearable startup Temple is acquiring London-based longevity medicine practice Longevous for an undisclosed amount, adding clinical and scientific expertise ahead of the launch of its device.
Longevous founders Robert Mohr and Avi Roy, along with their team, will join Temple full-time, Goyal said in a post on X. Mohr will become chief medical officer, while Roy will serve as head of science.
'We are excited to share that Temple is acquiring Longevous, an evidence-based longevity medicine practice based in London,' Goyal said.
'The founders, Rob and Avi, and their team are joining Temple full time. They bring in deep clinical expertise and publication experience to work alongside our in-house science team as we prepare for launch,' he added.
Mohr is a board-certified physician with nearly two decades of clinical experience, including work in emergency medicine, and has moved into longevity medicine. Roy is an Oxford-trained biomedical scientist whose work has spanned longevity research and business.
Longevous will continue to operate as part of Temple, with Mohr and Roy continuing to look after its clients, according to Goyal.
Goyal said the deal developed from a chance meeting with the two founders at a dinner in London several months ago.
'A couple of months ago, I met Rob and Avi at a dinner event in London I had almost skipped. I am very glad I didn't,' he said.
Goyal said the pair noticed the Temple device he was wearing on the side of his forehead, prompting a discussion about the science behind the wearable.
'By the end of our last course, they asked me if they could try Temple for themselves,' he said.
Mohr and Roy then wore the device for about two months while going about their daily activities and became involved with Temple's science team.
According to Goyal, they tested the company's proprietary 'Entropy' metric, examined data collected by the device and challenged some of the assumptions behind its development. They also reviewed Temple's first scientific manuscripts before submission.
Temple is developing a wearable that attaches to the side of the forehead, around the temple, rather than being worn on the wrist.
The company said the position allows the device to collect signals related to cerebral blood flow, oxygenation and heart rate, and to monitor changes associated with activities including exercise, sleep, recovery and meditation.
At the centre of the product is a proprietary measure called Entropy, which Temple describes as an indicator of metabolic and sympathetic demand on the body.
Goyal has said the Entropy score updates every second on a scale of one to 250, with lower readings associated with deeper rest and higher readings with greater physical exertion.
Temple's claims about the device and its proprietary measurements are still being developed and evaluated. The company states in its terms of use that Temple is not a medical device and is not intended to diagnose, treat, cure or prevent medical conditions. It also said information from the device is intended for general wellness and informational purposes.
Goyal said on 21 August that Temple would soon begin taking pre-orders for a limited launch edition of the wearable, with shipments expected before the end of 2026. He said the latest version is less than half the size of the version previously shown.
The Economic Times reported in July that Temple was expected to price its debut wearable at Rs 75,000-80,000, targeting premium consumers. The indicative price would include lifetime access to Temple's software platform and a lifetime supply of adhesive tapes used to attach the device.
The report also said Temple was preparing for another funding round at a valuation of about $500 million.
Temple raised $54 million in its first funding round in February at a post-money valuation of about $190 million. Investors included Peak XV Partners, Steadview Capital, Dharana Capital and Info Edge Ventures, alongside more than 80 individual investors.